期刊文献+

前列腺腺癌中DD3(Pca3)基因的表达及其意义 被引量:1

Expression of DD3(Pca3) RNA and Its Significance in Prostatic Carcinoma
下载PDF
导出
摘要 目的评价DD3(Pca3)检测在前列腺腺癌活检标本病理诊断中的应用价值。方法观察DD3(Pca3)基因在196例前列腺腺癌和相关疾病前列腺标本中的原位杂交表达情况。结果在149例前列腺腺癌病例中,DD3(Pca3)染色阳性率为94.6%,染色情况与Gleason评分、患病年龄、血清总PSA值的关系无统计学意义。52例癌周有前列腺上皮内肿瘤(PIN)4,7例DD3(Pca3)阳性;149例腺癌癌巢周18例DD3(Pca3)阳性。在42例良性前列腺增生(BPH)中1例DD3(Pca3)阳性(2.38%)。结论 DD3(Pca3)是诊断前列腺腺癌有价值的阳性标记物。 Objective To evaluate the specificity and sensitivity of DD3 (Pea3) in detection of prostatic adenocarcinomas. Methods The expression of DD3 ( Pca3 ) was detected by in situ hybridization in 196 cases of prostatic adenocareinomas,42 cases of benign prostatic hyperplasia and 5 cases of atypical small acinar proliferation. Results DD3 (Pca3)RNA was positive in 94.6% cases of prostatic adenocarcinomas, regardless of Gleason score, age and serum PSA. However, DD3 ( Pca3 ) was also positive in high grade PIN that surrounded adeno- carcinomas (n = 52) ,47cases showed positive expression. In 149 cases of prostatic carcinoma, some normal-appearing glands situated in the immediate vicinity of cancer glands showed Pca3 expression. In 42 cases of BPH, lcases (2.38%) showed positive expression. Conclusion DD3 (Pca3)is a positive marker for diagnosis of prostatic adenocarcinomas,which has high sensitivity and specificity.
出处 《咸宁学院学报(医学版)》 2011年第4期299-301,共3页 Journal of Xianning Univarsity(medical Sciences)
基金 深圳市科技项目(20080036)
关键词 DD3(Pca3) 前列腺肿瘤 原位杂交 DD3 (Pca3) Prostatic neoplasms In situ hybridization
  • 相关文献

参考文献8

  • 1Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005 [ J ]. CA Cancer J Clin,2005,55 ( 1 ) : 10.
  • 2Lagana A,Bizzarri M,Marino A,et al.Solid phase extraction and high performance liquid chromatographic determination of doxophylline in plasma[J].Biomed Chromatogr,1990,4(5):205-207.
  • 3Tagliaro F,Dorizzi R,Frigerio A,et al.Non-extraction HPLC method for simultaneous measurement of dyphylline and doxofylline in serum[J].Clin Chem,1990,36(1):113-115.
  • 4van Gils MP, Stenman UH, Schalken JA, et al. Innovations in seram and urine markers in prostate cancer current eu- ropean researchin the P-Mark project[ J]. Eur Urol,2005, 48(6) :1031.
  • 5Balcerczak E, Mirowski M, Sasor A, et al. Expression of p65, DD3 and c-erbB2 genes in prostate cancer [ J ]. Neoplasma,2003,50:97.
  • 6Bialkowska-Hobrzanska H, Driman DK, Fletcher R. Ex- pression of human telomerase reverse transcriptase, Sur- vivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue [ J ]. Can J Urol,2006,13:2967.
  • 7Ion Popa, Yves Fradet, Genevieve Beaudry, et al. Identifi- cation of PCA3 (DD3) in prastaticcarcinoma by in situ hy- bridization[ J ]. Modem Pathology,2007,20 : 1121.
  • 8Schalken JA. Validation of molecular targets in prostate cancer[ J]. BJU Int,2005,96:23.

共引文献1

同被引文献8

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部